{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:51:51Z","timestamp":1790959911490,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>We conducted a prospective randomized clinical trial to investigate the combination of posttransplant cyclophosphamide (PTCy) and abatacept (Aba) for graft-versus-host disease (GVHD) prophylaxis. Patients with hematologic malignancies undergoing an allogeneic transplant from an 8\/8 matched related or unrelated donor were randomized 1:1 to tacrolimus and methotrexate (standard-of-care arm [SOC]) or PTCy on days +3 and +4, followed by Aba on an extended schedule: days +5, +14, and +28, and every 4 weeks up to day +168 (PTCy+Aba). All patients received peripherally collected stem cells. The primary end point was moderate and severe chronic GVHD at 1 year. Following US Food and Drug Administration approval of Aba for GVHD prophylaxis leading to change in institutional SOC, the trial was amended to enroll only on the PTCy+Aba arm. A total of 25 patients enrolled on PTCy+Aba, and 15 on SOC. The trial met its primary end point: Kaplan-Meier estimates of moderate and severe chronic GVHD were 0% on the PTCy+Aba and 65.8% on the SOC arm (P &amp;lt; .0001). GVHD-free, relapse-free survival (GRFS) was 62.5% on PTCy+Aba and 24.1% on SOC (P = .010). There were no treatment-related deaths on PTCy+Aba and 2 on SOC. Overall survival (PTCy+Aba, 92%; SOC, 80%; P = .28), disease-free survival (PCTy+Aba, 68%; SOC, 92.9%; P = .105), and infection rates at 1 year were similar. Grade 3\/4 acute GVHD rate was 4.2% on PTCy+Aba and 21.4% on SOC (P = .092). PTCy+Aba preserved regulatory T-cell proliferation and increased CD16+CD56dim cytotoxic natural killer cells. In conclusion, PTCy+Aba is well tolerated and associated with reduced chronic GVHD and improved GRFS. This trial was registered at www.ClinicalTrials.gov as #NCT03680092.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015094","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:54:53Z","timestamp":1750769693000},"page":"4336-4344","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept"],"prefix":"10.1182","volume":"9","author":[{"given":"Divya","family":"Koura","sequence":"first","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-1755","authenticated-orcid":false,"given":"Kaitlyn","family":"Dykes","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Goodman","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Mulroney","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Mangan","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7656-5249","authenticated-orcid":false,"given":"Tiffany N.","family":"Tanaka","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayad","family":"Hamdan","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah-Reum","family":"Jeong","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mirocha","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Clinical and Translational Science Institute and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0508-567X","authenticated-orcid":false,"given":"Qingyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Department of Pathology, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ogrodnik","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"McConnell","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Investigational Drug Service Pharmacy, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Maroge","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Padilla","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1097-4453","authenticated-orcid":false,"given":"Gerald P.","family":"Morris","sequence":"additional","affiliation":[{"name":"3Department of Pathology, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-4428","authenticated-orcid":false,"given":"Dimitrios","family":"Tzachanis","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"1","key":"2025082611215350300_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"2025082611215350300_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/bmt.2008.373","article-title":"Prophylaxis regimens for GVHD: systematic review and meta-analysis","volume":"43","author":"Ram","year":"2009","journal-title":"Bone Marrow Transpl"},{"issue":"25","key":"2025082611215350300_bib3","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"2025082611215350300_bib4","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025082611215350300_bib5","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2013.09.003","article-title":"In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial","volume":"19","author":"Koura","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"2025082611215350300_bib6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"issue":"211","key":"2025082611215350300_bib7","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"4","key":"2025082611215350300_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.2021013054","article-title":"Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning","volume":"139","author":"McCurdy","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025082611215350300_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025082611215350300_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2025082611215350300_bib11","first-page":"144","article-title":"Molecular mechanisms of T-cell anergy","volume":"78","author":"Kuklina","year":"2013","journal-title":"Biochemistry"},{"issue":"10","key":"2025082611215350300_bib12","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1080\/1042819042000219494","article-title":"Intrinsic and extrinsic regulation of T lymphocyte quiescence","volume":"45","author":"Tzachanis","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025082611215350300_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41409-020-01002-1","article-title":"CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies","volume":"56","author":"Jaiswal","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2025082611215350300_bib14","doi-asserted-by":"crossref","first-page":"e83913","DOI":"10.1371\/journal.pone.0083913","article-title":"CD86 is an activation receptor for NK cell cytotoxicity against tumor cells","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"2025082611215350300_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transpl"},{"issue":"25","key":"2025082611215350300_bib16","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"131","author":"Nahas","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2025082611215350300_bib17","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/bloodadvances.2023010545","article-title":"PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation","volume":"7","author":"Al-Homsi","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2025082611215350300_bib18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/15256","article-title":"Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance","volume":"5","author":"Li","year":"1999","journal-title":"Nat Med"},{"issue":"12","key":"2025082611215350300_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2025082611215350300_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"2025082611215350300_bib21","unstructured":"Schrimpf\n              D\n            \n          . RANDI3. Accessed 1 July 2025. https:\/\/dschrimpf.github.io\/randi3\/."},{"issue":"4","key":"2025082611215350300_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"issue":"6","key":"2025082611215350300_bib23","doi-asserted-by":"crossref","first-page":"605.e1","DOI":"10.1016\/j.jtct.2024.03.010","article-title":"Long-term follow-up of abatacept, post-transplantation cyclophosphamide, and sirolimus-based haploidentical transplantation in younger patients with nonmalignant diseases","volume":"30","author":"Jaiswal","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2025082611215350300_bib24","doi-asserted-by":"crossref","first-page":"9636897241265249","DOI":"10.1177\/09636897241265249","article-title":"A difficult case of calcineurin inhibitor neurotoxicity post-haploidentical HCT with a successful novel solution: cytotoxic T-lymphocyte-associated protein 4-immunoglobulin blockade for GVHD prophylaxis","volume":"33","author":"Dykes","year":"2024","journal-title":"Cell Transpl"},{"issue":"8","key":"2025082611215350300_bib25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2020.05.005","article-title":"CTLA4Ig in an extended schedule along with sirolimus improves outcome with a distinct pattern of immune reconstitution following post-transplantation cyclophosphamide-based haploidentical transplantation for hemoglobinopathies","volume":"26","author":"Jaiswal","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"2025082611215350300_bib26","doi-asserted-by":"crossref","first-page":"1296663","DOI":"10.3389\/fimmu.2023.1296663","article-title":"Separation of GVL from GVHD -location, location, location","volume":"14","author":"Teshima","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"2025082611215350300_bib27","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/TP.0000000000002941","article-title":"Alterations in NKG2A and NKG2C subsets of natural killer cells following Epstein-Barr virus reactivation in CTLA4Ig-based haploidentical transplantation is associated with increased chronic graft-versus-host disease","volume":"104","author":"Jaiswal","year":"2020","journal-title":"Transplantation"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4336\/2408697\/blooda_adv-2024-015094-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4336\/2408697\/blooda_adv-2024-015094-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:22:02Z","timestamp":1756221722000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4336\/537897\/A-prospective-clinical-trial-of-GVHD-prophylaxis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015094","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,26]]}}}